纳米银颗粒通过血脑屏障中剂量-效应关系的初步研究

汤京龙 ,  王硕 ,  刘丽 ,  王春仁 ,  奚廷斐

引用本文: 汤京龙, 王硕, 刘丽, 王春仁, 奚廷斐. 纳米银颗粒通过血脑屏障中剂量-效应关系的初步研究[J]. 无机化学学报, 2013, 29(5): 1025-1030. doi: 10.3969/j.issn.1001-4861.2013.00.150 shu
Citation:  TANG Jing-Long, WANG Shuo, LIU Li, WANG Chun-Ren, XI Ting-Fei. A Preliminary Study on the Dose-Effect Relation when Silver Nanoparticles Crossing through the Blood-Brain Barrier in vitro[J]. Chinese Journal of Inorganic Chemistry, 2013, 29(5): 1025-1030. doi: 10.3969/j.issn.1001-4861.2013.00.150 shu

纳米银颗粒通过血脑屏障中剂量-效应关系的初步研究

    通讯作者: 汤京龙,E-mail:tang-jinglong@163.com
  • 基金项目:

    北京市自然科学基金(No.3112024) (No.3112024)

    中国食品药品检定研究院中青年发展研究基金(No.2009C4)资助项目。 (No.2009C4)

摘要: 目的:本文研究了纳米银颗粒通过血脑屏障的剂量-效应关系,并对其通过血脑屏障的机理进行了初步推测。方法:研究中先建立了一个体外血脑屏障模型,再以纳米银颗粒为试验样品、微米银颗粒为对照样品,将不同浓度(25~400 μg·mL-1)的试样和对照样加入体外血脑屏障模型中共同培养4 h,之后利用ICP-MS测定通过血脑屏障的银颗粒百分比,并采用TEM观察BBB细胞的超微结构。结果:在相同剂量下,只有纳米银颗粒能通过血脑屏障;当纳米银颗粒的剂量小于100 μg·mL-1时,血脑屏障结构完整,有约2%纳米银颗粒通过血脑屏障;当纳米银颗粒剂量在100~400 μg·mL-1的范围内时,随纳米银颗粒剂量增加,纳米银颗粒通过血脑屏障的比率也会相应增加,而且血脑屏障结构被破坏的程度也相应增加。纳米银颗粒剂量为400 μg·mL-1时,有约15%的纳米银颗粒通过了血脑屏障。结论:初步推断,在剂量较低时,纳米银颗粒主要通过“细胞转运机理”通过血脑屏障,当剂量大到足以对脑毛细血管内皮细胞产生足够的细胞毒性时,“细胞毒性机理”将起主要作用。这也提示我们,即使剂量很小,纳米银颗粒仍能通过血脑屏障。因此在使用含有纳米银颗粒的医用产品甚至保健品时应持谨慎的态度。

English

  • 
    1. [1] Chen X, Schluesener H J. Toxicol Lett., 2008,176(1):1-12[1] Chen X, Schluesener H J. Toxicol Lett., 2008,176(1):1-12

    2. [2] Martinez-Castanon G A, Nino-Martinez N, Martinez-Guiterrez F, et al. J. Nanoparticle Res., 2008,10(8):1343-1348[2] Martinez-Castanon G A, Nino-Martinez N, Martinez-Guiterrez F, et al. J. Nanoparticle Res., 2008,10(8):1343-1348

    3. [3] Estores I M, Olsen D, Gómez-Marin O. J Rehabil Res Dev., 2008,45(1):135-139[3] Estores I M, Olsen D, Gómez-Marin O. J Rehabil Res Dev., 2008,45(1):135-139

    4. [4] Vlachou E, Chipp E, Shale E, et al. Burns., 2007,3(8):979- 985[4] Vlachou E, Chipp E, Shale E, et al. Burns., 2007,3(8):979- 985

    5. [5] Roe D, Karandikar B, Bonn-Savage N, et al. J Antimicrob Chemother., 2008,61(4):869-876[5] Roe D, Karandikar B, Bonn-Savage N, et al. J Antimicrob Chemother., 2008,61(4):869-876

    6. [6] Takenaka S, Karg E, Roth C, et al. Environ. Health Perspect., 2001,109(Suppl 4):547-551[6] Takenaka S, Karg E, Roth C, et al. Environ. Health Perspect., 2001,109(Suppl 4):547-551

    7. [7] Tang J L, Xiong L, Wang S, et al. J. Nanosci. Nanotechnol., 2009,9(8):4924-4932[7] Tang J L, Xiong L, Wang S, et al. J. Nanosci. Nanotechnol., 2009,9(8):4924-4932

    8. [8] TANG Jing-Long(汤京龙), XI Ting-Fei(奚廷斐), WEI Li-Na (魏丽娜), et al. Chinese J. Inorg. Chem. (Wuji Huaxue Xuebao), 2008,24(11):1827-1831[8] TANG Jing-Long(汤京龙), XI Ting-Fei(奚廷斐), WEI Li-Na (魏丽娜), et al. Chinese J. Inorg. Chem. (Wuji Huaxue Xuebao), 2008,24(11):1827-1831

    9. [9] Tang J L, Xiong L, Wang S, et al. Appl. Surface Sci., 2008,255(2):502-504[9] Tang J L, Xiong L, Wang S, et al. Appl. Surface Sci., 2008,255(2):502-504

    10. [10] TANG Jing-Long(汤京龙), XI Ting-Fei(奚廷斐), XIONG Ling(熊玲),et al. Transact. Mater. Heat Treat. (Cailiao Rechuli Xuebao), 2009,30(3):6-9[10] TANG Jing-Long(汤京龙), XI Ting-Fei(奚廷斐), XIONG Ling(熊玲),et al. Transact. Mater. Heat Treat. (Cailiao Rechuli Xuebao), 2009,30(3):6-9

    11. [11] Tang J L, Xiong L, Zhou G F,et al. J. Nanosci. Nanotechnol., 2010,10(10):6313-6317[11] Tang J L, Xiong L, Zhou G F,et al. J. Nanosci. Nanotechnol., 2010,10(10):6313-6317

    12. [12] CHENG Ling-Zhong(成令钟), ZHONG Cui-Ping(钟翠萍), CAI Wen-Qin(蔡文琴). Contemporary Histology(现代组织 学). Shanghai: Scientific and Technological Literature Publishing House, 2003.[12] CHENG Ling-Zhong(成令钟), ZHONG Cui-Ping(钟翠萍), CAI Wen-Qin(蔡文琴). Contemporary Histology(现代组织 学). Shanghai: Scientific and Technological Literature Publishing House, 2003.

    13. [13] U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry and FDA Premarket and Design Control Reviewers Medical Device Use-Safety: Incorporating Human Factors Engineering into Risk Management[N]. [2011-08-20]. http://www.fda.gov/ MedicalDevices/ DeviceRegulationand Guidance/Guidance Documents/ucm193096.htm[13] U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry and FDA Premarket and Design Control Reviewers Medical Device Use-Safety: Incorporating Human Factors Engineering into Risk Management[N]. [2011-08-20]. http://www.fda.gov/ MedicalDevices/ DeviceRegulationand Guidance/Guidance Documents/ucm193096.htm

    14. [14] State Food and Drug Administration(国家食品药品监督管 理局). YY/T 0316-2008 Medical devices Application of risk management to medical devices [S]. Beijing: Standards Press of China, 2009.[14] State Food and Drug Administration(国家食品药品监督管 理局). YY/T 0316-2008 Medical devices Application of risk management to medical devices [S]. Beijing: Standards Press of China, 2009.

  • 加载中
计量
  • PDF下载量:  0
  • 文章访问数:  1051
  • HTML全文浏览量:  134
文章相关
  • 收稿日期:  2012-12-25
  • 网络出版日期:  2013-01-21
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

/

返回文章